Table 2.

Association between clinical characteristics and T-bet+

T-bet−/lowT-bet+/high
(n = 566)(n = 48)
CharacteristicNumber (%)Number (%)Pa
Number of recurrences76 (13.4)1 (2.1)
Menopausal status
 Pre199 (35.1)22 (45.8)0.3168
 Peri31 (5.5)1 (2.1)
 Post336 (59.4)25 (52.1)
Lymphatic invasionb
 Yes83 (14.7)5 (10.4)0.5236
 No482 (85.3)43 (89.6)
Tumor size
 ≤0.5 cm24 (4.2)1 (2.1)0.0045
 >0.5 to 1 cm114 (20.1)1 (2.1)
 >1 to 2 cm238 (42.1)23 (47.9)
 >2 to 5 cm171 (30.2)22 (45.8)
 >5 cm19 (3.4)1 (2.1)
ERc
 Positive361 (63.8)13 (27.1)<0.0001
 Negative/equivocal120 (21.2)34 (70.8)
 NDd85 (15.0)1 (2.1)
Progesterone receptorc
 Positive323 (57.1)15 (31.3)<0.0001
 Negative/equivocal158 (27.9)32 (66.7)
 NDd85 (15.0)1 (2.0)
Histologic grade
 1159 (28.1)6 (12.5)<0.0001
 2209 (36.9)7 (14.6)
 3159 (28.1)30 (62.5)
 NDd39 (6.9)5 (10.4)
Adjuvant treatmentb
 Hormonal264 (46.7)11 (22.9)<0.0001
 Chemotherapy85 (15.0)22 (45.8)
 Both24 (4.3)0 (0.0)
 None192 (34.0)15 (31.3)
Age, years
 Mean55.2351.950.0656
 SD11.7612.88
 Minimum25.4922.43
 Maximum75.8274.18
 SEM0.491.86
  • aFisher exact test; ND groups were not used in testing.

  • bOne patient without data.

  • cFrom pathology reports.

  • dUnknown, not done, or missing.